British newspaper “Daily Mail”, in a new report, revealed that Scientists have come up with an almost 98% accurate blood test for Alzheimer’s disease, which can detect the disease two decades before symptoms begin, and scientists can measure the distinctive protein of the disease years before symptoms appear.
Brain protein helps in the emergence of Alzheimer’s disease
The newspaper said, named protein accumulates p-tau21 Abnormally in the brains of people with Alzheimer’s disease, which causes memory loss, and some leaks in the bloodstream, and researchers showed that the blood test to measure the level of p-tau217 98% accurate, describing the research advancement step as “very important.”
The report added, a simple blood test can diagnose Alzheimer’s disease, sometimes decades before the onset of symptoms, as scientists revealed a protein involved in brain cell damage that accumulates in the blood of patients up to 20 years before memory impairment, explaining that a protein P-tau217 Abnormally grouped in the brains of Alzheimer’s patients, and some small parts may leak into the bloodstream, and the researchers found a blood test that measures protein levels 98% accurate in identifying people with Alzheimer’s memory theft.
The newspaper said that the breakthrough was described as “very important” for developing treatments, explaining that there is no treatment for severe disease currently, but finding one will be easier if trials began in patients as early in the disease as possible, and a blood test can be used one day As a screening method to detect those at risk.
Experts said it could be used by general practitioners in less than five years once the test was improved, but others were less optimistic, warning of significant ethical concerns that must be addressed, as telling people that they would lose their memory would be devastating.
The newspaper added, about 850 thousand people in the UK suffer from dementia, and the most common form is Alzheimer’s disease, which represents about two-thirds of patients, since people with Alzheimer’s disease have tangles of proteins in the brain formed from Tau proteins, they also have plaques consisting of A protein called amyloid beta.
Amyloid beta and tau protein begins to accumulate before any cognitive symptoms appear, such as memory loss and confusion. However, it is important to note that there is no cure for Alzheimer’s disease. The research included an international team from Sweden and the United States, two studies presented today at the International Conference of the Association Alzheimer’s.
I looked at a subset of Britten Tau, called “ p-tau217, As researchers in the United States found this protein p-tau217 “It accumulates in the cerebrospinal fluid, which is a clear, colorless liquid in the body found in the brain and spinal cord, for Alzheimer’s patients before the emergence of cognitive symptoms, levels increase with the development of the disease, and can accurately predict the formation of amyloid plaques that appear in the brain of patients, researchers have developed a method to measure Protein intake p-tau217 And other tau fragments in 4 ml of blood.
They found protein levels p-tau217 In the blood, similar to cerebrospinal fluid, it was very low in healthy volunteers but elevated in patients with amyloid plaques.
“Our results support the idea that tau forms in the blood may be useful in detecting and diagnosing Alzheimer’s,” said lead researcher Randall Batman, professor of neuroscience at Washington University School of Medicine in St. Louis. “Scientists at Lund University, Sweden, found that protein levels” tau217 p- “7 times higher in the blood of people with Alzheimer’s disease than those who do not have this condition.
Blood protein levels increase to 20 years before symptoms of dementia appear, long before the disease appeared in brain scans, with more than 1,400 people enrolled in the study, according to the publication in the medical journal. JAMA Gamma
He revealed that the blood test was 98% accurate in identifying patients with Alzheimer’s disease, depending on the progression of their disease..
Lead author Dr. Oscar Hanson said: “This test, once verified and confirmed, opens the possibility of early diagnosis of Alzheimer’s disease, which is very important for clinical trials that evaluate new treatments that may stop or slow down the disease process..